التفاصيل البيبلوغرافية
| العنوان: |
Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study). |
| المؤلفون: |
Shoji, Tadahiro1 (AUTHOR) tshoji@iwate-med.ac.jp, Takatori, Eriko1 (AUTHOR) tnagasaw@iwate-med.ac.jp, Nagasawa, Takayuki1 (AUTHOR) mkagabu@iwate-med.ac.jp, Kagabu, Masahiro1 (AUTHOR) babatsu@iwate-med.ac.jp, Baba, Tsukasa1 (AUTHOR), Shigeto, Tatsuhiko2 (AUTHOR) t-shigeto@hirosaki-u.ac.jp, Matsumura, Yukiko2 (AUTHOR) y-matsu@hirosaki-u.ac.jp, Shimizu, Dai3 (AUTHOR) shimizud@doc.med.akita-u.ac.jp, Terada, Yukihiro3 (AUTHOR) teraday@doc.med.akita-u.ac.jp, Seino, Manabu4 (AUTHOR) m-seino@med.id.yamagata-u.ac.jp, Ohta, Tsuyoshi4 (AUTHOR) oota-t@med.id.yamagata-u.ac.jp, Nagase, Satoru4 (AUTHOR) nagases@med.id.yamagata-u.ac.jp, Shigeta, Shogo5 (AUTHOR) shogo.shigeta.a4@tohoku.ac.jp, Tokunaga, Hideki5 (AUTHOR) hideki.tokunaga.a1@tohoku.ac.jp, Shimada, Muneaki5 (AUTHOR) muneaki.shimada.b7@tohoku.ac.jp, Kaiho-Sakuma, Michiko6 (AUTHOR) michiko-kaihou@miyagi-pho.jp, Furukawa, Shigenori7 (AUTHOR) s-furu@infoseek.jp, Soeda, Shu7 (AUTHOR) s-soeda@fmu.ac.jp, Watanabe, Takafumi7 (AUTHOR) t-wata@fmu.ac.jp, Takahashi, Fumiaki8 (AUTHOR) ftakahas@iwate-med.ac.jp |
| المصدر: |
Cancers. Nov2024, Vol. 16 Issue 22, p3801. 11p. |
| مصطلحات موضوعية: |
*THERAPEUTIC use of antineoplastic agents, *PLATINUM compounds, *DRUG resistance in cancer cells, *CANCER relapse, *OVARIAN tumors, *BEVACIZUMAB, *ANTINEOPLASTIC agents, *TREATMENT effectiveness, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *CANCER chemotherapy, *MEDICAL records, *ACQUISITION of data, *COMPARATIVE studies, *PROGRESSION-free survival, *ADVERSE health care events, *OVERALL survival, *EVALUATION |
| مصطلحات جغرافية: |
JAPAN |
| مستخلص: |
Simple Summary: We evaluated the efficacy of bevacizumab (BEV) in first-line chemotherapy for clear cell carcinoma (CCC). We categorized patients with advanced clear cell carcinoma (CCC) who received platinum-based first-line chemotherapy into a non-BEV group and a BEV group, and compared the progression-free survival (PFS), overall survival (OS), response rates, adverse events, and platinum agent-resistant recurrence rates. The PFS was improved and response rates were higher in the BEV group. One patient in the BEV group had grade 4 gastrointestinal perforation, although no treatment-related death was reported. First-line chemotherapy with BEV in advanced CCC showed the potential for high response rates and an improved PFS. Objective: The usefulness of bevacizumab (BEV) as first-line chemotherapy for advanced ovarian clear cell carcinoma (CCC) was retrospectively evaluated at Tohoku Gynecologic Cancer Unit institutions. Patients and Methods: A total of 81 patients (52 patients without BEV and 29 with BEV) with advanced ovarian CCC who received initial platinum-based chemotherapy were enrolled. We selected 26 patients each without and with BEV according to propensity score matching methods, and compared the platinum-resistant recurrence rate, response rate, progression-free survival (PFS), overall survival (OS), and adverse events between the two groups. Results: The objective response rates for the patients with measurable disease in the non-BEV and BEV groups were 60.0% and 95.5%, respectively (p = 0.007). The recurrence of platinum-resistant patients was observed in 50.0% of the non-BEV group and 23.1% of the BEV group (p = 0.117). The median PFS was 12 and 22 months, respectively (p = 0.034), and the median OS was 32 and 47 months, respectively (p = 0.223). In the BEV group, grade 3 hypertension and proteinuria occurred in two patients, and thrombosis and carboplatin hypersensitivity occurred in one patient. Grade 4 gastrointestinal perforation occurred in one patient. Conclusions: First-line chemotherapy with BEV in advanced CCC showed the potential for high response rates and improved PFS. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder